Trial intelligence / Profile preview

Phase 2 trial of inhaled unfractionated heparin in hospitalized COVID-19 patients

RBR-8r9hy8fPhase 2Not yet recruiting

Sponsor
Galeno Research Center
Start
Jan 2021
Modality
Small Molecules, Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 2, open-label trial of heparin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Galeno Research Center. Planned start Jan 2021; status: not yet recruiting.

02

Drugs

heparin
03

Conditions

coronavirus disease 2019 (COVID-19)

Beyond the preview

Go deeper on RBR-8r9hy8f.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on RBR-8r9hy8f.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call